About the Authors
- Carlos Kramm
-
Roles Investigation, Methodology, Writing – review & editing
Affiliations Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States of America, Universidad de Los Andes, Facultad de Medicina, Las Condes, Santiago, Chile
- Ruben Gomez-Gutierrez
-
Roles Data curation, Investigation, Methodology, Writing – review & editing
Affiliations Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States of America, Department of Cell Biology, University of Malaga, Malaga, Spain
- Claudio Soto
-
Roles Resources
Affiliation Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States of America
- Glenn Telling
-
Roles Resources
Affiliation Prion Research Center, Colorado State University, Fort Collins, CO, United States of America
- Tracy Nichols
-
Roles Conceptualization, Investigation, Resources, Writing – review & editing
Affiliation Veterinary Services, APHIS, United States Department of Agriculture, Fort Collins, CO, United States of America
- Rodrigo Morales
-
Roles Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Writing – original draft
* E-mail: Rodrigo.MoralesLoyola@uth.tmc.edu
Affiliations Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States of America, CIBQA, Universidad Bernardo OHiggins. Santiago, Chile
Competing Interests
Dr. Morales and Dr. Soto are listed as inventors in one patent related to the PMCA technology (“Methods for estimating prion concentration in fluids and tissue by quantitative PMCA” US20110311997A1). Dr. Soto is inventor on several patents related to the PMCA technology and is currently Founder, Chief Scientific Officer and Vice-President of Amprion Inc, a biotech company focusing on the commercial utilization of PMCA for diagnosis of various neurodegenerative diseases. This does not alter our adherence to PLOS ONE policies on sharing data and materials.